Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Limited treatment options are available for stage IIIB/IV non‐small cell lung cancer (NSCLC). Nivolumab, a programmed cell death‐1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Hida, Toyoaki, Nishio, Makoto, Nogami, Naoyuki, Ohe, Yuichiro, Nokihara, Hiroshi, Sakai, Hiroshi, Satouchi, Miyako, Nakagawa, Kazuhiko, Takenoyama, Mitsuhiro, Isobe, Hiroshi, Fujita, Shiro, Tanaka, Hiroshi, Minato, Koichi, Takahashi, Toshiaki, Maemondo, Makoto, Takeda, Koji, Saka, Hideo, Goto, Koichi, Atagi, Shinji, Hirashima, Tomonori, Sumiyoshi, Naoki, Tamura, Tomohide
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://ncbi.nlm.nih.gov/pubmed/28266091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13225
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak